tbuckley/cabot-search huggingface dataset:
Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology
Authors: Karen A. Autio, Valentina Boni, Rachel W. Humphrey, Aung Naing
Journal: Clinical Cancer Research (2019)

The deep and durable antitumor effects of antibody-based immunotherapies such as immune checkpoint inhibitors (ICIs) have revolutionized oncology and transformed the therapeutic landscape for many cancers. Several anti-programmed death receptor 1 and anti-programmed death receptor ligand 1 antibodies have been approved for use in advanced solid tumors, including melanoma, non-small cell lung cancer, bladder cancer, and other cancers. ICIs are under development across many tumor types and preliminary results are compelling. However, ICIs have been associated with severe immune-related adverse events (irAEs), including rash, diarrhea, colitis, hypophysitis, hepatotoxicity, and hypothyroidism, which in some cases lead to high morbidity, are potentially life-threatening, and limit the duration of treatment. The incidence of severe irAEs increases further when programmed cell death-1 and programmed cell death ligand-1 inhibitors are combined with anti-CTLA-4 and/or other multidrug regimens. Probody therapeutics, a new class of recombinant, proteolytically activated antibody prodrugs are in early development and are designed to exploit the hallmark of dysregulation of tumor protease activity to deliver their therapeutic effects within the tumor microenvironment (TME) rather than peripheral tissue. TME targeting, rather than systemic targeting, may reduce irAEs in tissues distant from the tumor. Probody therapeutic technology has been applied to multiple antibody formats, including immunotherapies, Probody drug conjugates, and T-cell-redirecting bispecific Probody therapeutics. In preclinical models, Probody therapeutics have consistently maintained anticancer activity with improved safety in animals compared with the non-Probody parent antibody. In the clinical setting, Probody therapeutics may expand or create therapeutic windows for anticancer therapies.
Comparison of ABL1 and Gusb Reference Genes in the qRT-PCR Analysis of Halving Time and Early Molecular Response to TKI Therapy in Patients with Chronic Myeloid Leukemia
Authors: Joanna Wącław, Magdalena Zawada, Sylwia Czekalska, Bogdan Ochrem, Tomasz Sacha
Journal: Blood (2016)
Risk management strategy for reducing therapeutic plasma exchange‐related allergic reactions
Authors: Taegeun Lee, John Jeongseok Yang, Sihwan Kim, Hye‐jin Lee, Dae‐Hyun Ko, Sang‐Hyun Hwang, Hyouk‐Soo Kwon, Heung‐Bum Oh
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).
Authors: Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson, Dong-Wook Kim, Ian W. Flinn, Yeow-Tee Goh, Pedro Enrique Dorlhiac-Llacer, Kimmo Porkka, Mineo Kurokawa, Carmino DeSouza, Yaping Shou, Neil J. Gallagher, Ariful Haque, Hagop Kantarjian, Timothy P. Hughes
Journal: Blood (2010)
Prognostic Significance of DNA/Cig Flow Cytometry Assay in the ‘'era” of Novel Therapies in Multiple Myeloma (MM).
Authors: Xenofon Papanikolaou, Jackie Szymonifka, Susann Szmania, Katie Stone, Sarah Waheed, Saad Z Usmani, Christoph Heuck, Frits van Rhee, Joshua Epstein, Antje Hoering, Bart Barlogie
Journal: Blood (2012)
A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis
Authors: Michael Scordo, Gunjan L. Shah, Satyajit Kosuri, Diego Adrianzen Herrera, Sean Devlin, Molly A. Maloy, Jimmy Nieves, Taylor Borrill, Scott T. Avecilla, Richard C. Meagher, Richard J. O'Reilly, Guenther Koehne, Boglarka Gyurkocza, Hugo Castro-Malaspina, Roni Tamari, Miguel Perales, Sergio A. Giralt, Brian C. Shaffer
Journal: Blood (2016)
Inhibition of Interleukin-6 (IL-6) Reverses Anemia In Patients with Advanced Non Small Cell Lung Cancer (NSCLC): Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Authors: Michael W. Schuster, James R Rigas, Sergey V Orlov, Branislav Milovanovic, Kumar Prabhash, Jeffrey T Smith
Journal: Blood (2010)
Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Authors: Daniel W. Lee, Nirali N Shah, Maryalice Stetler-Stevenson, Marianna Sabatino, Cindy Delbrook, Kelly Richards, James N Kochenderfer, Steven A. Rosenberg, David Stroncek, Alan S. Wayne, Crystal L Mackall
Journal: Blood (2013)
Polymorphisms Of Human Leukocyte Antigen-G Gene and Clinical Outcome Of Patients With Chronic Lymphocytic Leukemia
Authors: Gabriela Klimkiewicz-Wojciechowska, Olga Grzybowska-Izydorczyk, Maciej Borowiec, Krystyna Wyka, Marta Chmielewska, Barbara Cebula-Obrzut, Hanna Makuch-Lasica, Tadeusz Robak, Krzysztof Warzocha, Wojciech Mlynarski, Ewa Lech-Maranda
Journal: Blood (2013)
Evaluation of Ph+/CD34+ Residual Cells in Chronic Myeloid Leukemia Patients after Long Lasting Treatment with Imatinib Mesylate.
Authors: Monica Bocchia, Elisabetta Abruzzese, Micaela Ippoliti, Simona Calabrese, Alessandro Gozzetti, Maria Teresa Pirrotta, Rosaria Crupi, Daniela Tozzuoli, Francesco Lauria
Journal: Blood (2005)
Abundance of Alternative Splicing Events and Differentiation Stage-Specific Changes in Splicing Suggest A Major Role in Regulation of Gene Expression During Late Erythropoiesis
Authors: Harold Pimentel, Jie Li, Marilyn Parra, Dana Ghanem, Sherry Gee, Jingping Hu, Xiuli An, Narla Mohandas, Lior Pachter, John G. Conboy
Journal: Blood (2012)
Final analysis of survival outcomes in the KSCC1501A trial of up-front therapy for HER2-negative advanced gastric cancer
Authors: Akitaka Makiyama, Katsunori Shinozaki, Tomomi Kashiwada, Hirofumi Kawanaka, Hiroaki Tanioka, Yoshihiro Okita, Masaru Fukahori, Naomi Hayashi, Mototsugu Shimokawa, Hiroshi Saeki, Eiji Oki, Eishi Baba, Hideo Baba, Masaki Mori
Journal: Annals of Oncology (2019)
Treatment with Rituximab, CHOP and Highly Active Antiretroviral Therapy (HAART) in AIDS-Related Diffuse Large B-Cell Lymphomas (DLBCL). Study of 60 Patients.
Authors: Josep-María Ribera, Albert Oriol, Mireia Morgades, Eva González-Barca, Pilar Miralles, Armando Lopez-Guillermo, Andres Lopez, Blanca Xicoy, Eugenia Abella, Santiago Gardella, Marta García, Joan Bargay, Katy Perez-Equiza, Javier Briones, Lluis Rodriguez, Mariano Provencio, Lourdes Escoda, Alfons Soler, Miguel Canales, Antonio Asensio, Antonio Romero, Secundino Ferrer, Evarist Feliu
Journal: Blood (2005)
HiSpots®: A novel ex vivo patient-derived 3D model of glioblastoma.
Authors: Jo Brown, Malik Zaben, Florian Siebzehnrubl, William P Gray
Journal: Neuro-Oncology (2019)

Abstract There are limited chemotherapeutic options for glioblastoma, which contributes to its poor prognosis. Established cell lines have many phenotypic differences from their original tumours, and drugs showing success in animal models often fail to translate to humans. HiSpots® aim to provide a representative 3D in vitro model of glioblastoma using ex vivo human tumour samples, suitable for mechanistic studies. HiSpots® are a high-density 3D cell culture technique. Cancer and microenvironment cells are mechanically and enzymatically isolated from fresh resected or biopsied tumours, seeded onto PTFE membranes and cultured on an air-liquid interface. Cultures were stained for beta-III tubulin (TUJ1), glial fibrillary acidic protein (GFAP), nestin, and ionized calcium binding adapter molecule 1 (IBA1) to identify tumour cells and microglia. Serum-containing and serum-free media were compared. HiSpots® were created at three densities: low, medium and high, for comparison. Medium density HiSpots® best supported TUJ1+GFAP+Nestin+ tumour cells, and the density did not affect the proportion of microglia. Medium and high density HiSpots® formed multiple cell layers, creating structures up to 40μm thick with variable cell type distribution. Medium and high density HiSpots® and tumour cells were best supported in serum-free media. Medium density HiSpots® cultured in serum-free media have been demonstrated as the best choice to support the heterogeneity of glioblastoma. These HiSpots® contain mostly tumour cells and microglia. HiSpots® therefore allow for the culture of human glioblastoma cells, including microenvironmental microglia. These HiSpot® models will be evaluated as a model for mechanistic studies in the future.
A Novel Murine Model of Human Disseminated Multiple Myeloma with A Subcutaneous Human Bone Chip from an Adult Donor Confers Proliferative Advantage and Is Suitable for the In Vivo Evaluation of Novel Drugs
Authors: Enrique M. Ocio, Laura San-Segundo, Juan Blanco, Teresa Hernández-Iglesias, Diego Fernández-Lázaro, Teresa Paíno, Mercedes Garayoa, Enrique Álava, Fernando Jiménez-Barredo, Elena Díaz-Rodríguez, Atanasio Pandiella, J.F San Miguel
Journal: Blood (2010)
Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)
Authors: Justyna Bartoszko, Tony Panzerella, Anthea Lau, Naheed Alam, Aaron D Schimmer, Matthew D. Seftel, Andre C Schuh, Mohamed Shanavas, Karen W.L. Yee, Vikas Gupta
Journal: Blood (2014)
Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.
Authors: Khaled M. Ramadan, Joseph M. Connors, Abdulwahab J. Al-Tourah, Randy D. Gascoyne, Kevin Song, Michael J. Barnett, Stephen H. Nantel, Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Julye Lavoie, Donna L. Forrest, Donna E. Hogge, Nicholas J. Voss, Ryan Brinkman, Clayton A. Smith, Cynthia L. Toze
Journal: Blood (2006)
Peptide Vaccination Against Cytomegalovirus (CMV) Elicits Immunological and Clinical Responses after Allogeneic Stem Cell Transplantation Even from a CMV Seronegative Donor
Authors: Michael Schmitt, Anita Schmitt, Markus Wiesneth, Angela Hückelhoven, Zeguang Wu, Juergen Kuball, Lei Wang, Peter Schauwecker, Susanne Hofmann, Marlies Götz, Birgit Michels, Birgit Maccari, Patrick Wuchter, Thomas Mertens, Paul Schnitzler, Hartmut Döhner, Anthony D. Ho, Donald Bunjes, Peter Dreger, Hubert Schrezenmeier, Jochen Greiner
Journal: Blood (2016)
Frequency of Amyloid Subtyping Among Patients with Immunoglobulin Light-Chain Amyloidosis Referred for High-Dose Chemotherapy and Autologous Stem Cell Transplant
Authors: Andrew J. Cowan, David G. Coffey, Teresa S. Hyun, Pamela S. Becker, Damian J. Green, Leona A Holmberg, Ajay K Gopal, Edward N. Libby
Journal: Blood (2016)
Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study.
Authors: Andre Goy, Steven Bernstein, Brad Kahl, Benjamin Djulbegovic, Michael Robertson, Sven de Vos, Elliot Epner, Amrita Krishnan, John Leonard, Sagar Lonial, Edward Stadtmauer, Owen O’Connor, Hongliang Shi, Anthony Boral, Richard Fisher
Journal: Blood (2007)
Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms
Authors: Dai Chihara, Hagop M. Kantarjian, Kate J Newberry, Farhad Ravandi, Naval G. Daver, Prithviraj Bose, Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Gautam Borthakur, Marina Konopleva, Guillermo Garcia-Manero, Uday R. Popat, Jorge E. Cortes, Srdan Verstovsek
Journal: Blood (2016)
The CXCR4 Antagonist AMD3100 Has Dual Effects, Initially Enhancing and Later Inhibiting Survival and Proliferation, in Myeloid Leukemia Cells in Vitro.
Authors: Ha-Yon Kim, Ji-Young Hwang, Seong-Woo Kim, Gak-Won Yun, Young-Joon Yang, Hyo-Jin Lee, Deog-Yeon Jo
Journal: Blood (2009)
AML SCT-BFM 2007: Results of the Prospective Hematopoietic Stem Cell Transplantation (HCT) Trial of the Berlin-Frankfurt-MÃ¼nster (BFM) Study Group for Children with Very High Risk Acute Myeloid Leukemia
Authors: Martin G. Sauer, Peter J. Lang, Michael H. Albert, Peter Bader, Daniel Breuer, Ursula Creutzig, Matthias K. Eyrich, Johann Greil, Bernd Gruhn, Wolfgang Holter, Thomas Klingebiel, Bernhard Kremens, Heiko vd Leyen, Christine Mauz-Körholz, Roland Meisel, Kirsten Mischke, Ingo Müller, Charlotte M. Niemeyer, Christina Peters, Dirk Reinhardt, Claudia Rossig, Paul G. Schlegel, Ansgar S. Schulz, Johanna Schrum, Petr Sedlacek, Brigitte Strahm, Wilhelm Woessmann, Martin Zimmermann, Rupert Handgretinger, Arndt Borkhardt
Journal: Blood (2017)
γ-Globin, a Tumor-Associated Antigen for Juvenile Myelomonocytic Leukemia (JMML): A Cell-Based Approach To Identify Tumor Antigenic Epitopes That Are Naturally Processed and Presented.
Authors: Naoto Hirano, Marcus O. Butler, Zhinan Xia, Seiji Kojima, Lee M. Nadler
Journal: Blood (2004)
Prolonged Remissions with Autologous and Allogeneic Stem Cell Transplantation for Burkitt’s Lymphoma: Long Term Follow-Up at a Single Institution.
Authors: Purvi Gada, Todd Defor, Daniel J. Weisdorf, Jeffrey S. Miller, Paul J. Orchard, Margaret L. MacMillan, Mukta Arora, Marcie Tomblyn, Linda J. Burns
Journal: Blood (2005)
The Leukemia-Associated Protein BTG1 Is Required for ATF4-Mediated Cellular Stress Responses
Authors: Laurensia Yuniati, Laurens T van der Meer, Geert JV Poelmans, Sander AL Palit, Caroline Rodenbach, Dorette S van IngenSchenau, Peter M Hoogerbrugge, Blanca Scheijen, Frank N van Leeuwen
Journal: Blood (2014)
How to modify the axis of a self-expandable metal stent to avoid malfunction in gastric outlet obstruction: a simple trick
Authors: Benedetto Mangiavillano, Francesco Auriemma, Mario Bianchetti, Alessandro Repici
Journal: Endoscopy (2019)

Malignant gastric outlet obstruction (GOO) is caused mainly by gastric or pancreaticobiliary neoplasms. GOO presents with uncomfortable symptoms, such as nausea, vomiting, and abdominal distension, leading to malnutrition and impaired quality of life [1] [2]. Endoscopic placement of a self‐expandable metal stent (SEMS) is widely accepted as nonsurgical palliative treatment of nonresectable malignant GOO [3]. However, the efficacy of the SEMS can be compromised, especially in patients affected by gastric antral neoplasia, in which GOO relief is not completely obtained. One of the reasons why gastric SEMS can be ineffective is possibly due to the impact of the proximal end of the stent at the great curvature of the gastric body ([Fig. 1 a]).
Efficacy of Single-Agent Decitabine in Relapsed and Primary Refractory (rel/ref) Acute Myeloid Leukemia (AML)
Authors: Andrew Hantel, Niloufer Khan, Richard A. Larson, Lucy A. Godley, Michael J. Thirman, Andrew Artz, Olatoyosi Odenike, Hongtao Liu, Jane E. Churpek, Darren King, Elizabeth Rich, Kwang Jin Choi, Randall W. Knoebel, Wendy Stock
Journal: Blood (2015)
Estimation of Dabigatran Plasma Concentrations in the Perioperative Setting. an Ex-Vivo Study Using Dedicated Coagulation Assays
Authors: Jonathan Douxfils, Sarah Lessire, Anne-Sophie Dincq, Maximilien Gourdin, Damien Gheldof, Justine Baudar, Bernard Chatelain, Jean-Michel Dogné, François Mullier
Journal: Blood (2014)
Cytotoxicity of the Recombinant Human Arginase (BCT-100) Against Acute Myeloid Leukaemia (AML)
Authors: Francis J Mussai, Sharon Egan, Joseph Higginbotham-Jones, Anthony Lo, Margaret Ng, Tracey A Perry, Justin Loke, Andrew D Beggs, Guy Pratt, Pamela R Kearns, Paul Cheng, Carmela DeSanto
Journal: Blood (2014)
A study of the renal hypofunction and accompanying adverse events in breast cancer patients treated with palbociclb
Authors: Mayu Morimoto, Yoichi Naito, Kanako Mamishin, Yoshiko Ishihara, Shota Kusuhara, Yumi Fujimoto, Kenichi Harano, Takahiro Kogawa, Nobuaki Matsubara, Ako Hosono, Toru Mukohara, Reiko Matsui, Toshikatsu Kawasaki
Journal: Annals of Oncology (2019)
External Validation of the Revised PAM Score for Patients with AML Scheduled for Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Frederike Kollinger, Jan Moritz Middeke, Maria Hardtmann, Christian Klesse, Friedrich Stölzel, Martin Wermke, Malte von Bonin, Katja Sockel, Cornelia S Link, Christoph Röllig, Christian Thiede, Uwe Platzbecker, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig
Journal: Blood (2016)
Rituximab Prophylaxis of EBV Reactivation after Alternative Donor Transplants Following Anti-Thymocyte Globulin-Based Conditioning Regimens.
Authors: Andrea Bacigalupo, Alida Dominietto, Monica Soracco, Anna Maria Raiola, Maria Teresa Van Lint, Teresa Lamparelli, Adalberto Ibatici, Francesca Gualandi, Francesco Frassoni, Elisabetta Tedone
Journal: Blood (2008)
Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients
Authors: Robyn Scherber, Tiziano Barbui, Alessandro M. Vannucchi, Francesco Passamonti, Giovanni Barosi, Alessandro Rambaldi, Maria L Ferarri, Amylou Dueck, Ayalew Tefferi, Ruben A. Mesa
Journal: Blood (2010)
Risk Factors Predicting Outcomes for Primary Refractory Hodgkin Lymphoma Patients Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation
Authors: Gunjan L Shah, Kurt S Bantilan, Stephanie L Verwys, Susan J McCall, Joachim Yahalom, Matthew J. Matasar, Alison J Moskowitz, Craig H. Moskowitz
Journal: Blood (2015)
A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia
Authors: Hai Zhou, Ping Qin, Qiang Liu, Chenglu Yuan, Yunliang Hao, Haiyan Zhang, Zhencheng Wang, Xuehong Ran, Xiaoxia Chu, Wenzheng Yu, Xin Wang, Yu Hou, Jun Peng, Ming Hou
Journal: American Journal of Hematology (2019)

We conducted a prospective, multicenter study to evaluate the efficacy and safety of low-dose decitabine in adult patients with refractory immune thrombocytopenia. Adult patients who did not respond to, did not tolerate, or were unwilling to undergo splenectomy, with either a baseline platelet count less than 30 × 109 /L or the presence of bleeding symptoms and further need of ITP-specific treatments, were enrolled. Patients received decitabine at 3.5 mg/m2 intravenously for three consecutive days per cycle, for three cycles with a four-week interval between cycles. All patients were assessed every week during the first 12 weeks and at four-week intervals thereafter. We screened 49 patients for eligibility. Four patients were excluded and 45 received decitabine. At the end of decitabine treatment, complete response was achieved in eight patients (17.78%), and partial response was achieved in 15 patients (33.33%). The median time to initial response was 28 days (range, 14-70 days). Furthermore, seven relapsed patients received decitabine retreatment and all showed platelet response, including one complete response and six partial responses. Sustained response rates at 6, 12 and 18 months were 44.44% (20/45), 31.11% (14/45) and 20.0% (9/45), respectively. For responders, immune thrombocytopenia-related symptoms, fatigue, psychological health, fear, and overall quality of life were significantly improved. Adverse events were observed in 13 (28.89%) patients. No serious adverse events were recorded. In conclusion, low dose decitabine is potentially effective and safe in the management of adults with refractory immune thrombocytopenia. This trial is registered with clinicaltrials.gov identifier: NCT01568333.
A Novel Therapy Protocol Improves Outcomes of Hematopoietic Stem Cell Transplantation in Juvenile Myelomonocytic Leukemia Patients Using Hypomethylation of Decitabine
Authors: Zhiyong Peng, Xiaoqin Feng, Huaying Liu, Yuelin He, Jianyun Liao, Xiaoting Liu, Chunfu Li
Journal: Blood (2018)
Imatinib Treatment Experience in a Public Health System, Minority Patient Population with Chronic Myelogenous Leukemia (CML).
Authors: Sunita Nathan, Shylendra Sreenivasappa, Luciano Fochesatto Filho, Decebal S. Griza, Tracy Smiley, Samuel Ofori-Ntow, Margaret C. Telfer, R. Catchatourian
Journal: Blood (2007)
David Oliver: Guidance tools won’t solve long hospital stays
Authors: David Oliver
Journal: BMJ (2019)

NHS England and NHS Improvement have launched “Where Best Next?”—a campaign to reduce the number of patients staying in hospital for three weeks or longer.1 Announcing the campaign, NHS England reported that 350 000 hospital patients had stayed for over 21 days in the past year.2 Getting 140 000 of them home sooner could free up 7000 beds, or “the equivalent of 15 large hospitals.” I have some big reservations about this claim.

Preventing avoidably long stays for older patients is a worthy ambition. Such stays put these patients at risk of physical and psychological harm3 and add to considerable pressure on a hospital system that already has the fewest …
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
Authors: J H Park, S F Jonas, G Bataillon, C Criscitiello, R Salgado, S Loi, G Viale, H J Lee, M V Dieci, S -B Kim, A Vincent-Salomon, G Curigliano, F André, S Michiels
Journal: Annals of Oncology (2019)
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
Authors: Theodore W Laetsch, Gary Douglas Myers, André Baruchel, Andrew C Dietz, Michael A Pulsipher, Henrique Bittencourt, Jochen Buechner, Barbara De Moerloose, Kara L Davis, Eneida Nemecek, Timothy Driscoll, Francoise Mechinaud, Nicolas Boissel, Susana Rives, Peter Bader, Christina Peters, Himalee S Sabnis, Stephan A Grupp, Gregory A Yanik, Hidefumi Hiramatsu, Heather E Stefanski, Lawrence Rasouliyan, Lan Yi, Sweta Shah, Jie Zhang, Andrew C Harris
Journal: The Lancet Oncology (2019)
Dysregulation of Nuclear Factor of Activated T-Cells (NFAT1) in Human T-Cell Acute Lymphocytic Leukemia (T-ALL): Possible Role of Inactivated NFAT1 in Leukemogenesis.
Authors: M. Kozik, M.L. Lesniewski, Y. Hegerfeldt, R.R. Brewka, L.R. Fanning, M.R. Finney, R.P. Weitzel, R. Sakthivel, Mary J. Laughlin
Journal: Blood (2006)
CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1
Authors: Jun Chen, Sha Jin, Paul Tapang, Stephen K Tahir, Morey Smith, John Xue, Haichao Zhang, Wenqing Gao, Yunsong Tong, Richard Clark, Justin L. Ricker, Thomas D Penning, Daniel H Albert, Darren C Phillips, Andrew J Souers, Joel D. Leverson
Journal: Blood (2014)
Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
Authors: Andrew D. Zelenetz, Gilles A. Salles, Kylie D Mason, Carla Casulo, Steven Le Gouill, Laurie H Sehn, Hervé Tilly, Guillaume Cartron, Martine ED Chamuleau, Andre Goy, Constantine S. Tam, Pieternella J Lugtenburg, Rebecca Elstrom, Thalia Farazi, Juan Liu, Edith Szafer-Glusman, Mehrdad Mobasher, Franck Morschhauser
Journal: Blood (2016)
VEGFR-1 (FLT-1), b1 Integrin and hERG K+ Channel Form a Macromolecular Signaling Complex in Acute Myeloid Leukemia Cells.
Authors: Annarosa Arcangeli, Serena Pillozzi, Maria F. Brizzi, Pietro A. Bernabei, Benedetta Bartolozzi, Roberto Caporale, Venere Basile, Vieri Boddi, Eugenio Torre, Luigi Pegoraro, Andrea Becchetti
Journal: Blood (2006)
Differential Gene Expression Involved In Angiogenesis, Metabolism, Cell Proliferation and Self-Renewal and Pluripotency In Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Authors: Jose F Falantes, Cristina Calderón, Pablo Trujillo, Beatriz Martin-Antonio, Jose González, Alvaro Urbano, Magdalena Carmona, Ildefonso Espigado
Journal: Blood (2010)